This is a news story, published by CNBC, that relates primarily to Zealand Pharma news.
For more Zealand Pharma news, you can click here:
more Zealand Pharma newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Danish biotech Zealand Pharma. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Zealand Pharma news, global pharma firm news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
separate obesity drug candidateCNBC
•Health
Health
81% Informative
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs.
CEO Adam Steensberg heralded early-stage trial results of its GLP-1 treatment in an interview with CNBC .
He said it's the company's separate obesity drug candidate, Petrelintide , that sets it apart.
Zealand Pharma CEO: "It's not something Zealand could even think about, manufacturing themselves" Steensberg ruled out growing speculation around a takeover, saying it's "definitely not part of our plans" But he noted that even with a significant $1 billion capital raise earlier this year , the company would need a partner.
VR Score
85
Informative language
87
Neutral language
34
Article tone
informal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links
